RNA Targeted Drug Discovery: From Pipe Dream to Reality
n-Lorem Foundation, ChemGenes Announce Collaboration to Support Manufacturing of Individualized Treatments for Patients with Ultra-Rare Diseases
Foundation’s partnership with [...]
Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Download PDF
n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases
Foundation’s collaboration with [...]
Antisense Technology: An Overview and Prospectus
Crooke, S.T., Baker, B.F., Crooke R.M., Liang, X.H.
Site-specific incorporation of 5′-methyl DNA enhances the therapeutic profile of gapmer ASOs
Vasquez, G., Freestone, G.C., Wan, W.B., Low, A., De Hoyos, C.L., Yu, J., Prakash, T.P., Østergaard, M.E., Liang, X.H., Crooke, S.T., Swayze, E.E., Migawa, M.T., Seth, P.P.
